Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 56.5% of revenues, temporarily offsetting legacy declines while lending credibility to the thrice raised FY2025 guidance. Otherwise, BMY faces numerous Patent cliffs for Opdivo/Eliquis and the Medicaid headwinds, which may pressure FY2026 results/cash flow generation.
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY and overtaking legacy drugs, supporting a bullish outlook. Despite modest 3% total revenue growth, BMY maintains robust margins, strong cash flow, and a 4.65% dividend yield, enhancing its defensive appeal.
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive compensation while awaiting pipeline catalysts.
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus, reflecting pipeline strength. Shares trade at a discount to peers with a 14% FCF yield, while multiple late-stage drugs and recent acquisitions support long-term growth.
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield
Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug declines and supporting a raised 2025 revenue outlook of $47.5–$48.0 billion. Trading at less than 8x FCF and offering a 4.65% dividend yield, BMY appears undervalued relative to peers on key profitability metrics.
